Comparative Pharmacology
Head-to-head clinical analysis: ANJESO versus BUTAZOLIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANJESO versus BUTAZOLIDIN.
ANJESO vs BUTAZOLIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
120 mg administered intravenously over 15 minutes, followed by 30 mg intravenously over 15 minutes, with the second dose given 12 to 24 hours after the first dose.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours in healthy adults. In elderly or renally impaired patients, half-life may extend to up to 6 hours.
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Approximately 70% renal (30% unchanged, 40% as glucuronide conjugate), 30% fecal/biliary.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Category C
Category C
NSAID
NSAID